The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
physostigmine salicylate · PHYSOSTIGMINE SALICYLATE .4 mg/mL · Injection · Intravenous · Provepharm Inc.
NDC 81284-0831-05 · 5 AMPULE in 1 CARTON / 5 mL in 1 AMPULE · UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| HF Acquisition Co LLC, DBA HealthFirst | PHYSOSTIGMINE SALICYLATE 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Provepharm Inc. | PHYSOSTIGMINE SALICYLATE .4 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Anticholium — NDC 81284-0831-05," retrieved September 3, 2026, https://drugdashboards.com/drug/81284083105.
Free to cite with attribution — see how the data is put together.